- Company
- Anticipation for the survival-extending effects of Fruzaqla
- by Hwang, byoung woo Sep 12, 2025 06:18am
- A new option has emerged for fourth-line metastatic colorectal cancer (CRC) treatment. Previously, there were no more drugs available to use, increasing expectations in clinical practice. In Korea, the survival-extending effect of Fruzaqla (fruquintinib) is evaluated as a potential solution to the unmet needs of CRC patients. The number of p
- Company
- Greenlight for launching KRAS inhibitors for lung cancer
- by Son, Hyung Min Sep 11, 2025 06:10am
- Next-generation KRAS inhibitors are emerging as a new game-changer in the lung cancer treatment market. While first-generation KRAS inhibitors, such as Amgen's Lumakras and BMS's Krazati, have been commercialized, concerns have risen regarding their limitations in terms of resistance and restricted indications. As a result, global pharmaceut
- Company
- ‘HIV Is No Longer a Target of Discrimination'
- by Hwang, byoung woo Sep 11, 2025 06:09am
- While advances in antiretroviral drugs have made human immunodeficiency virus (HIV) a manageable chronic disease, experts point out that social awareness remains stagnant. Amid the reality that the suicide risk among infected individuals in Korea is nearly twice as high as among non-infected individuals, academia, patient groups, and industry
- Company
- Could Spravato resolve treatment-resistant depression?
- by Hwang, byoung woo Sep 11, 2025 06:09am
- As Korea ranks first in suicide rates among OECD countries, the need for treatment support for ‘treatment-resistant depression’ is being emphasized. Experts stress the need for alternatives in treating treatment-resistant depression, a condition known to have a sevenfold higher risk of suicide attempts compared to general depression. On
- Company
- Will Balversa make progress toward reimb in Korea this year?
- by Eo, Yun-Ho Sep 10, 2025 06:14am
- Attention is focused on whether progress will be made in the insurance reimbursement listing process for ‘Balversa,’ the first targeted therapy for bladder cancer. According to industry sources, Janssen Korea’s FGFR inhibitor for urothelial carcinoma, Balversa (erdafitinib), passed review by the Cancer Disease Deliberation Committee of
- Company
- Samsung Biologics signs KRW 1.8T contract deal
- by Chon, Seung-Hyun Sep 10, 2025 06:13am
- Samsung Biologics announced on September 9 that it has signed a Contract Manufacturing Organization (CMO) agreement worth $1.294 billion (approximately KRW 1.800 trillion) with a U.S.-based pharmaceutical company This contract is the second-largest one in the company's history, following a deal worth approximately KRW 2 trillion with a Eur
- Company
- Will 'Tibsovo' be listed for reimbursement in H2?
- by Eo, Yun-Ho Sep 10, 2025 06:13am
- As 'Tibsovo' seeks insurance reimbursement for cholangiocarcinoma, a disease with limited treatment options, attention is being paid to whether it will achieve results in the second half of this year. According to industry sources, Servier's Tibsovo (ivosidenib) is currently under discussion for the review schedule for the Drug Reimbursem
- Company
- Early diagnosis and personalized therapy are key
- by Son, Hyung Min Sep 10, 2025 06:12am
- “The treatment options for rheumatoid arthritis (RA) have become far more diverse than in the past. Contrary to the past when management focused primarily on alleviating symptoms, today, with early diagnosis and tailored treatment strategies, it is possible to maintain long-term remission. Patients can now continue their daily lives with fe
- Company
- Launch of K-new drugs in the Chinese market is accelerated
- by Chon, Seung-Hyun Sep 10, 2025 06:12am
- New drugs developed in Korea are successively entering the Chinese market. Based on their commercial success in the Korean market, new P-CAB (Potassium-Competitive Acid Blocker) drugs for gastroesophageal reflux disease are quickly entering the approximately KRW 3 trillion-worth Chinese market. Fexuclue has become the second P-CAB to enter the C
- Company
- KIPO, IPTAB to introduce ‘advance invalidation notice’
- by Hwang, byoung woo Sep 9, 2025 06:13am
- The Korean Intellectual Property Office (KIPO) and the Intellectual Property Trial and Appeal Board (IPTAB) announced a reform plan introducing a pre-announcement system for invalidation decisions (“advance invalidation notice”) in patent invalidation trials, dividing opinions within the pharmaceutical industry. Led by the Korea Pharmace
